HRP950485A2 - Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence - Google Patents

Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence Download PDF

Info

Publication number: HRP950485A2
Authority: HR; Croatia
Prior art keywords: serotonin reuptake; selective serotonin; reuptake inhibitor; naltrexone; fluoxetine
Prior art date: 1994-09-19

Application number

HR08/308,859A

Other languages

English (en)

Croatian (hr)

Inventor

Leonard Cook

Original Assignee

Du Pont Merck Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-09-19

Filing date

1995-09-19

Publication date

1997-08-31

1995-09-19 Application filed by Du Pont Merck Pharma filed Critical Du Pont Merck Pharma

1997-08-31 Publication of HRP950485A2 publication Critical patent/HRP950485A2/hr

Links

229940124834 selective serotonin reuptake inhibitor Drugs 0.000 title claims abstract description 46
239000012896 selective serotonin reuptake inhibitor Substances 0.000 title claims abstract description 46
239000003401 opiate antagonist Substances 0.000 title claims abstract description 35
208000007848 Alcoholism Diseases 0.000 title claims abstract description 34
201000007930 alcohol dependence Diseases 0.000 title claims abstract description 26
238000011282 treatment Methods 0.000 title description 20
239000000203 mixture Substances 0.000 claims abstract description 42
238000000034 method Methods 0.000 claims abstract description 37
241000124008 Mammalia Species 0.000 claims abstract description 15
239000011885 synergistic combination Substances 0.000 claims abstract description 6
DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 claims description 49
229960003086 naltrexone Drugs 0.000 claims description 47
229960002464 fluoxetine Drugs 0.000 claims description 39
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 38
AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 15
AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 15
229960002296 paroxetine Drugs 0.000 claims description 15
VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims description 10
229960004038 fluvoxamine Drugs 0.000 claims description 9
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 claims description 9
229960002073 sertraline Drugs 0.000 claims description 9
WJBLNOPPDWQMCH-MBPVOVBZSA-N Nalmefene Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=C)O)CC1)O)CC1CC1 WJBLNOPPDWQMCH-MBPVOVBZSA-N 0.000 claims description 8
229960005297 nalmefene Drugs 0.000 claims description 8
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 claims description 6
229960004127 naloxone Drugs 0.000 claims description 5
229960001800 nefazodone Drugs 0.000 claims description 5
VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 claims description 5
229960004688 venlafaxine Drugs 0.000 claims description 5
PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 5
239000005557 antagonist Substances 0.000 claims description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 92
150000001875 compounds Chemical class 0.000 description 36
239000004480 active ingredient Substances 0.000 description 26
230000000694 effects Effects 0.000 description 25
241000700159 Rattus Species 0.000 description 23
239000000243 solution Substances 0.000 description 20
239000003814 drug Substances 0.000 description 16
239000002775 capsule Substances 0.000 description 12
239000002552 dosage form Substances 0.000 description 12
229940079593 drug Drugs 0.000 description 12
239000003826 tablet Substances 0.000 description 12
239000000047 product Substances 0.000 description 11
239000003795 chemical substances by application Substances 0.000 description 10
239000003937 drug carrier Substances 0.000 description 10
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
238000012360 testing method Methods 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
239000003887 narcotic antagonist Substances 0.000 description 9
AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 description 8
210000001035 gastrointestinal tract Anatomy 0.000 description 8
230000009467 reduction Effects 0.000 description 8
230000002829 reductive effect Effects 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
239000007788 liquid Substances 0.000 description 6
238000002360 preparation method Methods 0.000 description 6
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
239000003772 serotonin uptake inhibitor Substances 0.000 description 6
235000002639 sodium chloride Nutrition 0.000 description 6
230000002195 synergetic effect Effects 0.000 description 6
229920002472 Starch Polymers 0.000 description 5
229940000425 combination drug Drugs 0.000 description 5
230000035622 drinking Effects 0.000 description 5
235000019359 magnesium stearate Nutrition 0.000 description 5
230000000144 pharmacologic effect Effects 0.000 description 5
229920000642 polymer Polymers 0.000 description 5
239000008107 starch Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
239000005720 sucrose Substances 0.000 description 5
-1 (NTII) Chemical compound 0.000 description 4
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
241000282320 Panthera leo Species 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
239000013066 combination product Substances 0.000 description 4
229940127555 combination product Drugs 0.000 description 4
230000003993 interaction Effects 0.000 description 4
239000008101 lactose Substances 0.000 description 4
238000012417 linear regression Methods 0.000 description 4
238000002156 mixing Methods 0.000 description 4
239000008194 pharmaceutical composition Substances 0.000 description 4
230000004044 response Effects 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
230000001629 suppression Effects 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000012730 sustained-release form Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
230000009471 action Effects 0.000 description 3
230000008485 antagonism Effects 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
229960001653 citalopram Drugs 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
229960002563 disulfiram Drugs 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000000843 powder Substances 0.000 description 3
238000000611 regression analysis Methods 0.000 description 3
229940076279 serotonin Drugs 0.000 description 3
235000000346 sugar Nutrition 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
229960002791 zimeldine Drugs 0.000 description 3
OYPPVKRFBIWMSX-SXGWCWSVSA-N zimeldine Chemical compound C=1C=CN=CC=1C(=C/CN(C)C)\C1=CC=C(Br)C=C1 OYPPVKRFBIWMSX-SXGWCWSVSA-N 0.000 description 3
QQGISFDJEJMKIL-JAIQZWGSSA-N (5z)-5-[[3-(hydroxymethyl)thiophen-2-yl]methylidene]-10-methoxy-2,2,4-trimethyl-1h-chromeno[3,4-f]quinolin-9-ol Chemical compound C1=CC=2NC(C)(C)C=C(C)C=2C2=C1C=1C(OC)=C(O)C=CC=1O\C2=C/C=1SC=CC=1CO QQGISFDJEJMKIL-JAIQZWGSSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
WIYUZYBFCWCCQJ-IFKAHUTRSA-N Naltrindole Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC=C3NC=25)O)CC1)O)CC1CC1 WIYUZYBFCWCCQJ-IFKAHUTRSA-N 0.000 description 2
102000003840 Opioid Receptors Human genes 0.000 description 2
108090000137 Opioid Receptors Proteins 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
206010001584 alcohol abuse Diseases 0.000 description 2
208000025746 alcohol use disease Diseases 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000006399 behavior Effects 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
230000007177 brain activity Effects 0.000 description 2
OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000012876 carrier material Substances 0.000 description 2
239000001913 cellulose Chemical class 0.000 description 2
229920002678 cellulose Chemical class 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
230000008859 change Effects 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
239000003086 colorant Substances 0.000 description 2
238000002648 combination therapy Methods 0.000 description 2
238000011284 combination treatment Methods 0.000 description 2
239000007891 compressed tablet Substances 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
238000013211 curve analysis Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
239000007884 disintegrant Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
239000008187 granular material Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
239000008297 liquid dosage form Substances 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
235000010981 methylcellulose Nutrition 0.000 description 2
238000012986 modification Methods 0.000 description 2
230000004048 modification Effects 0.000 description 2
ZHVWWEYETMPAMX-PCWWUVHHSA-N naltriben Chemical compound N1([C@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC=C3OC=25)O)CC1)O)CC1CC1 ZHVWWEYETMPAMX-PCWWUVHHSA-N 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
229940005483 opioid analgesics Drugs 0.000 description 2
239000003182 parenteral nutrition solution Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000003285 pharmacodynamic effect Effects 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
229920000747 poly(lactic acid) Polymers 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
230000000862 serotonergic effect Effects 0.000 description 2
230000013275 serotonin uptake Effects 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
235000010356 sorbitol Nutrition 0.000 description 2
241000894007 species Species 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
230000009044 synergistic interaction Effects 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
239000002691 unilamellar liposome Substances 0.000 description 2
XDIYNQZUNSSENW-UUBOPVPUSA-N (2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XDIYNQZUNSSENW-UUBOPVPUSA-N 0.000 description 1
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
ICONPJDAXITIPI-UXYWFNEESA-N (4r,4as,7ar,12bs)-4a,9-dihydroxy-3-methyl-3-prop-2-enyl-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-3-ium-7-one;iodide Chemical compound [I-].O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CC[N+](C)(CC=C)[C@@H]3CC5=CC=C4O ICONPJDAXITIPI-UXYWFNEESA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
GLQPTZAAUROJMO-UHFFFAOYSA-N 4-(3,4-dimethoxyphenyl)benzaldehyde Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=O)C=C1 GLQPTZAAUROJMO-UHFFFAOYSA-N 0.000 description 1
WXOUFNFMPVMGFZ-BDQAUFNLSA-N 7-Benzylidenenaltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC(/C5=O)=C\C=2C=CC=CC=2)O)CC1)O)CC1CC1 WXOUFNFMPVMGFZ-BDQAUFNLSA-N 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
229940126062 Compound A Drugs 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
108010049140 Endorphins Proteins 0.000 description 1
102000009025 Endorphins Human genes 0.000 description 1
108010092674 Enkephalins Proteins 0.000 description 1
NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
206010027940 Mood altered Diseases 0.000 description 1
GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 1
RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
STOXPPZNSYPOHZ-BQRPEJFJSA-N N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC(=C3NC=25)N=C=S)O)CC1)O)CC1CC1 Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C3=CC=CC(=C3NC=25)N=C=S)O)CC1)O)CC1CC1 STOXPPZNSYPOHZ-BQRPEJFJSA-N 0.000 description 1
UIQMVEYFGZJHCZ-SSTWWWIQSA-N Nalorphine Chemical compound C([C@@H](N(CC1)CC=C)[C@@H]2C=C[C@@H]3O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 UIQMVEYFGZJHCZ-SSTWWWIQSA-N 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
206010037180 Psychiatric symptoms Diseases 0.000 description 1
229940124639 Selective inhibitor Drugs 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical class OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
APSUXPSYBJVPPS-YHMFJAFCSA-N ac1l3op1 Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CC=2C=3C[C@]4(O)[C@]67CCN(CC8CC8)[C@H]4CC=4C7=C(C(=CC=4)O)O[C@H]6C=3NC=25)O)CC1)O)CC1CC1 APSUXPSYBJVPPS-YHMFJAFCSA-N 0.000 description 1
IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
229940098194 antabuse Drugs 0.000 description 1
230000002221 antabuse Effects 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
235000012216 bentonite Nutrition 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
229920001400 block copolymer Polymers 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229940095672 calcium sulfate Drugs 0.000 description 1
235000011132 calcium sulphate Nutrition 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
229940075614 colloidal silicon dioxide Drugs 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000013267 controlled drug release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
238000001647 drug administration Methods 0.000 description 1
239000000890 drug combination Substances 0.000 description 1
238000004049 embossing Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000002662 enteric coated tablet Substances 0.000 description 1
229960004756 ethanol Drugs 0.000 description 1
238000005562 fading Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000003205 fragrance Substances 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000012886 linear function Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
150000004701 malic acid derivatives Chemical class 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012907 medicinal substance Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
230000007510 mood change Effects 0.000 description 1
229960000938 nalorphine Drugs 0.000 description 1
AJPSBXJNFJCCBI-YOHUGVJRSA-N naloxonazine Chemical compound C([C@@H](N(CC1)CC=C)[C@]2(O)CC\C3=N/N=C4/[C@H]5[C@]67CCN(CC=C)[C@@H]([C@@]7(CC4)O)CC4=CC=C(C(O5)=C46)O)C4=CC=C(O)C5=C4[C@@]21[C@H]3O5 AJPSBXJNFJCCBI-YOHUGVJRSA-N 0.000 description 1
229940065778 narcan Drugs 0.000 description 1
239000000025 natural resin Substances 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
239000007935 oral tablet Substances 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
235000019629 palatability Nutrition 0.000 description 1
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001610 polycaprolactone Polymers 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
229940035613 prozac Drugs 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000003014 reinforcing effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
229960003660 sertraline hydrochloride Drugs 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
229910000342 sodium bisulfate Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000010972 statistical evaluation Methods 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000000946 synaptic effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000000057 synthetic resin Substances 0.000 description 1
229920003002 synthetic resin Polymers 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000037317 transdermal delivery Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
235000012141 vanillin Nutrition 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
229940020965 zoloft Drugs 0.000 description 1
229930195724 β-lactose Natural products 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Addiction (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Psychiatry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

HR08/308,859A 1994-09-19 1995-09-19 Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence HRP950485A2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US30885994A	1994-09-19	1994-09-19

Publications (1)

Publication Number	Publication Date
HRP950485A2 true HRP950485A2 (en)	1997-08-31

Family

ID=23195683

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR08/308,859A HRP950485A2 (en)	1994-09-19	1995-09-19	Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence

Country Status (11)

Country	Link
US (1)	US5958962A (fr)
EP (1)	EP0782445B1 (fr)
AT (1)	ATE214276T1 (fr)
AU (1)	AU3419995A (fr)
CA (1)	CA2197554A1 (fr)
CO (1)	CO4410317A1 (fr)
DE (1)	DE69525847T2 (fr)
DK (1)	DK0782445T3 (fr)
HR (1)	HRP950485A2 (fr)
WO (1)	WO1996009047A1 (fr)
ZA (1)	ZA957891B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6001848A (en) *	1996-03-25	1999-12-14	The Regents Of The University Of California	Bromocriptine for the treatment of alcoholics diagnosed with the D2 dopamine receptor DRD2 A1 allele
PT980241E (pt) *	1997-07-01	2004-03-31	Pfizer Prod Inc	Formas de dosagem encapsuladas em gelatina de sertralina em solucao
CN1256085C (zh)	1997-07-01	2006-05-17	美国辉瑞有限公司	舍曲林盐和舍曲林的缓释剂型
WO2001032178A1 (fr) *	1999-10-29	2001-05-10	Novo Nordisk A/S	Utilisation de piperidines 3,4-substituees
US6696088B2 (en)	2000-02-08	2004-02-24	Euro-Celtique, S.A.	Tamper-resistant oral opioid agonist formulations
US20040253627A1 (en) *	2000-07-07	2004-12-16	Grant Zimmermann	System and method for multidimensional evaluation of combinations of compositions
US7034036B2 (en) *	2000-10-30	2006-04-25	Pain Therapeutics, Inc.	Inhibitors of ABC drug transporters at the blood-brain barrier
EP1262196A3 (fr) *	2001-05-23	2002-12-18	Pfizer Products Inc.	Combinaison d'un inhibiteur de la recapture de monoamines et d'un antagoniste opioique pour l'utilisation dans l'alcoolisme et la dépendance alcoolique
US7034059B2 (en)	2001-07-02	2006-04-25	Sepracor Inc.	Methods of using norfluoxetine
PL368612A1 (en) *	2001-08-14	2005-04-04	Biotie Therapies Corporation	Method of treating alcoholism or alcohol abuse
US20140271788A1 (en)	2013-03-15	2014-09-18	Monosol Rx, Llc	Sublingual and buccal film compositions
JP4545584B2 (ja) *	2002-05-17	2010-09-15	デュークユニバーシティ	肥満を治療するための方法
US20050215552A1 (en) *	2002-05-17	2005-09-29	Gadde Kishore M	Method for treating obesity
DE10237057A1 (de) *	2002-08-09	2004-03-25	Grünenthal GmbH	Opioid-Rezeptor-Antagonisten in Pflasterformulierungen
MXPA05011557A (es) *	2003-04-29	2006-03-09	Orexigen Therapeutics Inc	Composiciones para afectar perdida de peso.
EP1870096A3 (fr) *	2003-04-29	2011-04-20	Orexigen Therapeutics, Inc.	Compositions pour influencer la perte de poids
AU2005206139B2 (en)	2004-01-13	2009-02-26	Duke University	Compositions of an anticonvulsant and an antipsychotic drug for affecting weight loss
US20060160750A1 (en) *	2004-01-13	2006-07-20	Krishnan K R R	Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en)	2004-01-13	2010-05-11	Duke University	Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060100205A1 (en) *	2004-04-21	2006-05-11	Eckard Weber	Compositions for affecting weight loss
EP2292220A3 (fr)	2005-11-22	2012-01-04	Orexigen Therapeutics, Inc.	Compositions et procédés pour augmenter la sensibilité à l'insuline
WO2007089318A2 (fr) *	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions et méthodes de réduction de la boulimie
WO2007064586A1 (fr) *	2005-11-28	2007-06-07	Orexigen Therapeutics, Inc.	Procede de traitement de desordres dus a l’anxiete
US20070212307A1 (en) *	2006-02-10	2007-09-13	Daniel Wermeling	Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
CN101588795A (zh)	2006-11-09	2009-11-25	奥雷西根治疗公司	包含中间快速溶解层的分层药物制剂
AU2007319472B2 (en)	2006-11-09	2013-01-17	Nalpropion Pharmaceuticals Llc	Methods Of Administering Weight Loss Medications
US9138430B2 (en) *	2007-12-27	2015-09-22	Mylan Specialty L.P.	Formulation and method for the release of paroxetine in the large intestine
US20110144145A1 (en)	2008-05-30	2011-06-16	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
US20100168119A1 (en) *	2008-11-05	2010-07-01	Pharmorx, Inc.	Compositions and methods for minimizing or reducing agonist-induced desensitization
CN102724878A (zh)	2010-01-11	2012-10-10	奥雷西根治疗公司	在重度抑郁症患者中提供体重减轻疗法的方法
KR20220042241A (ko)	2012-06-06	2022-04-04	오렉시젠 세러퓨틱스 인크.	과체중 및 비만의 치료 방법
EP2950799B1 (fr)	2013-01-30	2019-12-04	Pharmorx Therapeutics, Inc.	Traitement de la dépression et autres maladies avec un agent à faible dose
US8969371B1 (en)	2013-12-06	2015-03-03	Orexigen Therapeutics, Inc.	Compositions and methods for weight loss in at risk patient populations
WO2015095644A1 (fr)	2013-12-20	2015-06-25	AntiOP, Inc.	Compositions de naloxone intranasales et leurs procédés de préparation et d'utilisation
EP3946547A4 (fr)	2019-03-26	2023-01-18	Pocket Naloxone Corp.	Dispositifs et procédés d'administration de compositions pharmaceutiques
US11278709B1 (en)	2021-03-12	2022-03-22	Pocket Naloxone Corp.	Drug delivery device and methods for using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4777173A (en) *	1987-03-25	1988-10-11	Bristol-Myers Company	Method for treatment of alcohol abuse
JPH06507416A (ja) *	1991-05-07	1994-08-25	ダイナジェン・インコーポレーテッド	禁煙のための調節された持続的放出伝達システム
US5366990A (en) *	1991-11-14	1994-11-22	Reid Larry D	Method for treating alcohol abuse and alcoholism
US5512593A (en) *	1993-03-02	1996-04-30	John S. Nagle	Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor

1995
- 1995-09-07 CA CA002197554A patent/CA2197554A1/fr not_active Abandoned
- 1995-09-07 DK DK95931014T patent/DK0782445T3/da active
- 1995-09-07 DE DE69525847T patent/DE69525847T2/de not_active Expired - Fee Related
- 1995-09-07 AU AU34199/95A patent/AU3419995A/en not_active Abandoned
- 1995-09-07 WO PCT/US1995/010987 patent/WO1996009047A1/fr not_active Ceased
- 1995-09-07 AT AT95931014T patent/ATE214276T1/de not_active IP Right Cessation
- 1995-09-07 EP EP95931014A patent/EP0782445B1/fr not_active Expired - Lifetime
- 1995-09-19 CO CO95043013A patent/CO4410317A1/es unknown
- 1995-09-19 HR HR08/308,859A patent/HRP950485A2/hr not_active Application Discontinuation
- 1995-09-19 ZA ZA957891A patent/ZA957891B/xx unknown
- 1995-10-13 US US08/542,747 patent/US5958962A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2197554A1 (fr)	1996-03-28
ZA957891B (en)	1997-03-19
DE69525847T2 (de)	2002-09-05
DK0782445T3 (da)	2002-05-06
CO4410317A1 (es)	1997-01-09
ATE214276T1 (de)	2002-03-15
US5958962A (en)	1999-09-28
EP0782445B1 (fr)	2002-03-13
DE69525847D1 (de)	2002-04-18
EP0782445A1 (fr)	1997-07-09
AU3419995A (en)	1996-04-09
WO1996009047A1 (fr)	1996-03-28

Publication	Publication Date	Title
HRP950485A2 (en)	1997-08-31	Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6071918A (en)	2000-06-06	Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
Mello et al.	1989	Buprenorphine suppresses cocaine self-administration by rhesus monkeys
US3966940A (en)	1976-06-29	Analgetic compositions
EP2612553B1 (fr)	2016-06-08	Compositions et procédés pour la prophylaxie et le traitement de la toxicomanie
US3773955A (en)	1973-11-20	Analgetic compositions
US4761429A (en)	1988-08-02	Enkephalinase and endorphinase inhibitors as anti-craving compositions
US3879555A (en)	1975-04-22	Method of treating drug addicts
US20250302771A1 (en)	2025-10-02	Treatment of opioid use disorder, opioid withdrawal symptoms and chronic pain
US8481599B2 (en)	2013-07-09	Compositions and methods for increasing compliance with therapies using aldehyde dehydrogenase inhibitors and treating alcoholism
AU740504B2 (en)	2001-11-08	Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, motion sickness and vertigo
KR20020081271A (ko)	2002-10-26	물질 남용의 치료 방법
Gardell et al.	1997	Combination of naltrexone and fluoxetine on rats’ propensity to take alcoholic beverage
Homayoun et al.	2002	The effect of cyclosporin A on morphine tolerance and dependence: involvement of L-arginine/nitric oxide pathway
US20250367189A1 (en)	2025-12-04	2-bromo-lysergic acid diethylamide for substance abuse
EP1000623A1 (fr)	2000-05-17	Utilisation de l' epinastine comme agent antitussif
AU1256501A (en)	2001-06-06	A method of treating substance addiction
Craig	1988	Analgesics and Sports Medicine
Gardell et al.	1997	Luis zyxwvutsrqponmlkjihgfedcb
De Quincey	2004	high doses of pure agonists. 2 Such complex prop
Qureshi et al.	2003	Pharmacotherapies of addiction
Highfield	1994	Effects of Ng-nitro-L-arginine, a nitric oxide synthase inhibitor, on a cellular model of morphine tolerance
Short	1995	Evidence for an Endogenous Opioid Component in Nicotine Dependence and Abstinence Syndrome
Fekkes et al.	2002	Norharman and alcohol-dependency in male wistar rats
Cannoy-Searoy	1991	The Anti-Opiate Role of Neuropeptide FF in Narcotic Tolerance and Respiration

Legal Events

Date	Code	Title
1997-08-31	A1OB	Publication of a patent application
1998-02-27	AIPI	Request for the grant of a patent on the basis of a substantive examination of a patent application
2003-10-22	ODBI	Application refused